164 related articles for article (PubMed ID: 1604162)
1. [Recombinant human erythropoietin in uremic patients in substitute treatment].
Canaud B; Mion C
Rev Prat; 1992 Feb; 42(4):432-40. PubMed ID: 1604162
[TBL] [Abstract][Full Text] [Related]
2. The effect of recombinant human erythropoietin (r-Hu EPO) administration on the blood chemistries and composition in uremic rats.
Kozioł M; Ksiazek P; Feldo M; Spasiewicz D; Michalak J; Kleinrok Z
Ann Univ Mariae Curie Sklodowska Med; 1994; 48 Suppl 3():61-6. PubMed ID: 8192533
[TBL] [Abstract][Full Text] [Related]
3. [Recombinant human erythropoietin: 18 months of continuous use in substitution hemodialysis].
Canaud B; Polito-Bouloux C; Rivory JP; Donnadieu P; Taib J; Florence P; Mion C
Nephrologie; 1990; 11(1):5-10. PubMed ID: 2374643
[TBL] [Abstract][Full Text] [Related]
4. [Treatment of anemia with recombinant human erythropoietin and the bone marrow response in uremic patients undergoing periodic hemodialysis].
García Martín F; Carrascosa Vallejo T; Martín Escobar E; Val Begueria J; Martín Hernández R; de Arriba G; Teno C; Salvatierra J
Rev Clin Esp; 1990 May; 186(9):419-22. PubMed ID: 2247677
[TBL] [Abstract][Full Text] [Related]
5. [Human recombinant erythropoietin (rH-EPO) in chronic hemodialysis patients].
Jalil R; Vaccarezza A; Jara A; Lira P; Vial S; Serrano V
Rev Med Chil; 1990 Jun; 118(6):629-34. PubMed ID: 1775783
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic and pharmacodynamic studies on recombinant human erythropoietin.
Salmonson T
Scand J Urol Nephrol Suppl; 1990; 129():1-66. PubMed ID: 2255869
[TBL] [Abstract][Full Text] [Related]
7. Management of iron deficiency in renal anemia: guidelines for the optimal therapeutic approach in erythropoietin-treated patients.
Drüeke TB; Bárány P; Cazzola M; Eschbach JW; Grützmacher P; Kaltwasser JP; Macdougall IC; Pippard MJ; Shaldon S; van Wyck D
Clin Nephrol; 1997 Jul; 48(1):1-8. PubMed ID: 9247771
[TBL] [Abstract][Full Text] [Related]
8. Clinical efficacy of recombinant human erythropoietin in hemodialysis patients.
Mohini R
Semin Nephrol; 1989 Mar; 9(1 Suppl 1):16-21. PubMed ID: 2648516
[TBL] [Abstract][Full Text] [Related]
9. Recombinant human erythropoietin in predialysis patients.
Lim VS
Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):34-7. PubMed ID: 1928077
[TBL] [Abstract][Full Text] [Related]
10. The use of recombinant human erythropoietin (EPO) to correct the anemia of end-stage renal disease: a progress report.
Adamson W; Egrie JC; Browne JK; Downing MR; Eschbach W
Behring Inst Mitt; 1988 Aug; (83):188-92. PubMed ID: 3071336
[TBL] [Abstract][Full Text] [Related]
11. The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period.
Silverberg DS; Blum M; Agbaria Z; Deutsch V; Irony M; Schwartz D; Baruch R; Yachnin T; Steinbruch S; Iaina A
Clin Nephrol; 2001 Mar; 55(3):212-9. PubMed ID: 11316241
[TBL] [Abstract][Full Text] [Related]
12. Erythropoietin 1991--an overview.
Eschbach JW
Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):3-9. PubMed ID: 1928076
[TBL] [Abstract][Full Text] [Related]
13. Excessive level of parathyroid hormone may induce the reduction of recombinant human erythropoietin effect on renal anemia.
Fujita Y; Inoue S; Horiguchi S; Kuki A
Miner Electrolyte Metab; 1995; 21(1-3):50-4. PubMed ID: 7565462
[TBL] [Abstract][Full Text] [Related]
14. Treatment of the anemia with human recombinant erythropoietin in CAPD patients.
Miranda B; Selgas R; Riñon C; Fernandez-Zamorano A; Borrego F; Ortuño F; Lopez-Revuelta K; Torre A; Sanchez Sicilia L
Adv Perit Dial; 1990; 6():296-301. PubMed ID: 1982831
[TBL] [Abstract][Full Text] [Related]
15. Peritoneal dialysis adequacy during the r-Hu EPO treatment.
Baranowska-Daca E; Ksiazek A
Ann Univ Mariae Curie Sklodowska Med; 1994; 48 Suppl 3():51-60. PubMed ID: 8192532
[TBL] [Abstract][Full Text] [Related]
16. [Chemical structure, biotechnical production and clinical use of recombinant erythropoietin].
Fandrey JK; Jelkmann WE
Z Gesamte Inn Med; 1992 Jun; 47(6):231-8. PubMed ID: 1642021
[TBL] [Abstract][Full Text] [Related]
17. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
18. Erythropoietin use in peritoneal dialysis patients.
Zimmerman SW; Johnson CA
Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):38-41. PubMed ID: 1928078
[TBL] [Abstract][Full Text] [Related]
19. Effect of recombinant human erythropoietin on hospitalization of hemodialysis patients.
Churchill DN; Muirhead N; Goldstein M; Posen G; Fay W; Beecroft ML; Gorman J; Taylor DW
Clin Nephrol; 1995 Mar; 43(3):184-8. PubMed ID: 7774076
[TBL] [Abstract][Full Text] [Related]
20. Comparison of hemodialysis and peritoneal dialysis in the management of anemia related to chronic renal disease.
Korbet SM
Semin Nephrol; 1989 Mar; 9(1 Suppl 1):9-15. PubMed ID: 2648520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
